. Author manuscript; available in PMC: 2015 Aug 1.

Published in final edited form as: Am J Hematol. 2014 May 16;89(8):813–818. doi: 10.1002/ajh.23751

Table 2.

Association between Cytogenetics Subgroups with Overall Survival and AML Transformation

Cytogenetics Categories	Case#	Age^* (Years)	Alive /Dead	Overall Survival			AML Transformation
Cytogenetics Categories	Case#	Age^* (Years)	Alive /Dead	Time^* (Mon)	Hazard Ratio (95% CI)	P⁺	Rate	Hazard Ratio (95% CI)	P⁺
Normal karyotype	292	69	120/172	33	1		69 (23.6%)	1
Single abnormality	80	69	34/46	23
+8	17	69	6/11	22	1.55 (0.75 – 3.18)	0.235	5 (29.4%)	1.73 (1.03 – 6.34)	0.046
−7 or del(7q)	14	71	4/10	14	3.52 (3.89 – 13.16)	<0.001	6 (36%)	3.18 (1.72 – 14.64)	0.008
−Y	13	77	7/6	30	1.14 (0.48 – 2.79)	0.755	0	undefined
Del(20q)	11	72	4/7	24	1.44 (0.92 – 4.25)	0.076	2 (18%)	1.34 (0.28 – 7.62)	0.645
−X or del(Xq)	5	63	3/2	25	1.16 (0.26 – 4.21)	0.849	0	undefined
Other single	20	68	10/10	22	1.25 (0.67 – 2.33)	0.486	6 (30%)	1.17 (0.49 – 2.83)	0.734
2 abnormalities	20	67	3/17	16
−7 or del(7q) plus 1	6	63	1/5	14	3.46 (2.09 – 16.84)	0.038	4 (67%)	4.29 (3.29 – 19.84)	0.002
+8 plus 1	5	74	0/5	14	2.83 (1.458 – 7.48)	0.015	3 (60%)	4.42 (2.72 – 18.99)	0.006
Other two	9	77	3/6	18	1.99 (0.97 – 5.77)	0.064	4 (44%)	2.16 (1.69 – 8.77)	0.035
3 abnormalities	9	69	3/6	15	2.91 (1.74 – 16.29)	0.006	5 (56%)	5.13 (3.13 – 26.67)	<0.001
>3 abnormalities	16	68	3/13	8	9.44 (4.94 – 18.06)	<0.001	3 (19%)	3.68 (1.13 – 11.98)	0.031

Data presented as median.

⁺

Compared to normal karyotype, significant while p<0.05

AML: acute myeloid leukemia; Mon: months.